Entrada’s stock drops as DMD drug’s efficacy falls short

ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota. At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota. Entrada’s DMD drug failed to meet analyst expectations in the first cohort of a Phase I/II study in patients amendable to exon 44 skipping. Credit: MY STOCKERS / Shutterstock.com. Entrada Therapeutics’ stock value has dropped by more than 57% after the efficacy of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, failed to impress investors in the first portion of an early-stage…

Source: Clinical Trials Arena